Beijing Kawin Technology Share-Holding Co., Ltd. (SHSE: 688687)
Health Care · Biotechnology · CN
CN¥18.91
+3.39% today · -32.9% 1Y
Beijing Kawin Technology Share-Holding Co., Ltd. (SHSE: 688687) operates in the Biotechnology industry within the Health Care sector. The company is valued at $472.02M and employs 617 people.
Over the last twelve months the share price has lost 32.9%, trading between 14.61 and 29.81.
Tweenvest scores Beijing Kawin Technology Share-Holding Co., Ltd. across four factors: quality 73/100, value 56/100, growth 38/100, dividend 68/100. Its strongest factor is quality.
688687 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $472.02M
- Revenue (TTM)
- $181.24M
- P/E
- —
- EPS
- 0.06
- Dividend yield
- 1.32%
- Beta (5Y)
- 0.47
- 52-week high
- CN¥29.81
- 52-week low
- CN¥14.61
- Avg volume (3M)
- —
- Shares outstanding
- 167.44M
- Employees
- 617
- Next earnings
- —
About Beijing Kawin Technology Share-Holding Co., Ltd.
Established in 2008 and based in Beijing, China, Beijing Kawin Technology Share-Holding Co., Ltd. specializes in the research, development, and manufacturing of pharmaceutical products, with a primary emphasis on treatments for liver conditions within the Chinese market. Its key offerings include recombinant human interferon alfa-2b injection and compound glycyrrhizin. Beyond its own product line, the company supplies active pharmaceutical ingredients (APIs) and delivers comprehensive clinical research services for advancing biological products. These services encompass the fermentation and purification of drug substances, drug product formulation, and the creation of analytical methods. Beijing Kawin also offers contract manufacturing solutions. The company's global footprint includes serving customers in countries such as Pakistan, Colombia, the Philippines, Vietnam, Russia, and Cambodia, among others. Furthermore, it maintains strategic partnerships with entities like Legend Capital, Haitong Capital, and Cybernaut.
- ISIN
- CNE1000054C3
- Founded
- 2008
- Listed since
- Feb 8, 2021
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Blau Farmacêutica S.A.BOVESPA: BLAU3 | $477.46M | R$10.82 | +5.87% |
| Eupraxia Pharmaceuticals Inc.TSX: EPRX | $477.13M | CA$10.73 | +3.97% |
| Shanghai Kehua Bio-Engineering Co.,LtdSZSE: 002022 | $472.33M | CN¥6.12 | +9.09% |
| Laekna, Inc.SEHK: 2105 | $472.14M | HK$8.75 | +26.81% |
| Autolus Therapeutics plcNasdaqGS: AUTL | $471.11M | $1.77 | -2.21% |
| SanBio Company LimitedTSE: 4592 | $465.71M | ¥941.00 | -1.05% |
| Capricor Therapeutics, Inc.NasdaqGS: CAPR | $465.69M | $8.01 | -1.11% |
| Assembly Biosciences, Inc.NasdaqGS: ASMB | $464.63M | $22.82 | -0.57% |
Figures last refreshed Oct 4, 2026.